These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389 [TBL] [Abstract][Full Text] [Related]
32. Initial treatment for patients with CML. Goldman JM Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231 [TBL] [Abstract][Full Text] [Related]
33. Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. Myojo T; Hino N Intern Med; 2004 Feb; 43(2):126-30. PubMed ID: 15005255 [TBL] [Abstract][Full Text] [Related]
34. Targeted chronic myeloid leukemia therapy: Seeking a cure. Fausel C Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932 [TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749 [TBL] [Abstract][Full Text] [Related]
36. [The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment]. Zhang Y; Jiang Q; Qiu JY; Chen SS; Jiang B; Huang XJ Zhonghua Nei Ke Za Zhi; 2007 Aug; 46(8):648-50. PubMed ID: 17967235 [TBL] [Abstract][Full Text] [Related]
37. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208 [TBL] [Abstract][Full Text] [Related]
38. CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN BLAST CRISIS. Sarwar S; Siddiqui N; Zafar W; Fasih S; Basit A; Hameed A J Ayub Med Coll Abbottabad; 2015; 27(2):371-4. PubMed ID: 26411119 [TBL] [Abstract][Full Text] [Related]
39. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Mohamed AN; Pemberton P; Zonder J; Schiffer CA Clin Cancer Res; 2003 Apr; 9(4):1333-7. PubMed ID: 12684401 [TBL] [Abstract][Full Text] [Related]
40. Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate. Skalska-Sadowska J; Januszkiewicz-Lewandowska D; Derwich K; Pieczonka A; Samborska M; Wachowiak J Pediatr Blood Cancer; 2015 Jun; 62(6):1070-1. PubMed ID: 25631405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]